You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Dupixent hits all endpoints in prurigo nodularis trial

Sanofi and Regeneron’s monoclonal antibody (mAb) Dupixent (dupilumab) met all primary and key secondary endpoints in a Phase III trail for the chronic inflammatory skin disease prurigo nodularis.